Center for Vascular and Heart Research, Fralin Biomedical Research Institute, Virginia Tech, Roanoke, VA, 24016, USA.
Department of Pharmacology, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt.
Inflammopharmacology. 2024 Oct;32(5):2649-2680. doi: 10.1007/s10787-024-01535-7. Epub 2024 Aug 10.
Since the start of the pandemic, considerable advancements have been made in our understanding of the effects of SARS-CoV-2 infection and the associated COVID-19 on the hepatic system. There is a broad range of clinical symptoms for COVID-19. It affects multiple systems and has a dominant lung illness depending on complications. The progression of COVID-19 in people with pre-existing chronic liver disease (CLD) has also been studied in large multinational groups. Notably, SARS-CoV-2 infection is associated with a higher risk of hepatic decompensation and death in patients with cirrhosis. In this review, the source, composition, mechanisms, transmission characteristics, clinical characteristics, therapy, and prevention of SARS-CoV-2 were clarified and discussed, as well as the evolution and variations of the virus. This review briefly discusses the causes and effects of SARS-CoV-2 infection in patients with CLD. As part of COVID-19, In addition, we assess the potential of liver biochemistry as a diagnostic tool examine the data on direct viral infection of liver cells, and investigate potential pathways driving SARS-CoV-2-related liver damage. Finally, we explore how the pandemic has had a significant impact on patient behaviors and hepatology services, which may increase the prevalence and severity of liver disease in the future. The topics encompassed in this review encompass the intricate relationships between SARS-CoV-2, liver health, and broader health management strategies, providing valuable insights for both current clinical practice and future research directions.
自疫情开始以来，我们对 SARS-CoV-2 感染的影响以及 COVID-19 对肝脏系统的影响有了更深入的了解。COVID-19 有广泛的临床症状。它影响多个系统，根据并发症的不同，以肺部疾病为主。在患有慢性肝病 (CLD) 的人群中，COVID-19 的进展也在大型跨国人群中进行了研究。值得注意的是，SARS-CoV-2 感染与肝硬化患者肝失代偿和死亡的风险增加有关。在这篇综述中，阐明和讨论了 SARS-CoV-2 的来源、组成、机制、传播特点、临床特征、治疗和预防，以及病毒的演变和变异。这篇综述简要讨论了 SARS-CoV-2 感染对 CLD 患者的原因和影响。作为 COVID-19 的一部分，我们还评估了肝功能作为诊断工具的潜力，研究了直接感染肝细胞的病毒数据，并探讨了驱动 SARS-CoV-2 相关肝损伤的潜在途径。最后，我们探讨了大流行如何对患者行为和肝脏病学服务产生重大影响，这可能会增加未来肝脏疾病的患病率和严重程度。本综述涵盖了 SARS-CoV-2、肝脏健康和更广泛的健康管理策略之间的复杂关系，为当前的临床实践和未来的研究方向提供了有价值的见解。
